Trevena (NASDAQ:TRVN) Now Covered by StockNews.com

by · The Cerbat Gem

StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN – Free Report) in a research report report published on Monday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Trevena Price Performance

NASDAQ:TRVN opened at $1.69 on Monday. The company has a market cap of $1.45 million, a P/E ratio of -0.04 and a beta of 1.08. The firm’s fifty day moving average price is $3.15 and its two-hundred day moving average price is $5.72. Trevena has a one year low of $1.13 and a one year high of $19.23.

Trevena (NASDAQ:TRVN – Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share for the quarter. The business had revenue of $0.28 million for the quarter. As a group, equities research analysts expect that Trevena will post -32.25 earnings per share for the current year.

About Trevena

(Get Free Report)

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.

Further Reading